2020-2027 Analysis and Review Cilastatin Sodium Market

Cilastatin Sodium Market

Cilastatin Sodium Market by Clinical Application (Lower Respiratory Tract Infections, Urinary Tract Infections and Others) by Distribution Channel (Hospital Pharmacy, Retail Pharmacy and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2020 – 2027

23-07-2020 REP-HC-5141 40 Tables 110 pages Format

The cilastatin sodium market was valued at USD 786.8 Mn by 2019. Rising prevalence of lower respiratory tract infections primarily drives the cilastatin sodium market growth. Additionally, the significant increase in the number of people reported being suffering from urinary tract infection further accentuates the market growth.

Cilastatin Sodium Market

Cilastatin sodium is a chemical moiety that inhibits the human enzyme dehydropeptidase. It is clinically understood that renal dehydropeptidase is responsible for the degradation of imipenem antibiotic, hence it is used in combination with imipenem to prolong its antibacterial activity. It has a plasma protein binding of 40% and renal excretion of 98% respectively.

The major segments related to the cilastatin sodium market are: 

By Clinical Application (2017–2027; US$ Mn)

Lower Respiratory Tract Infections

Urinary Tract Infections

Others

By Distribution Channel (2017–2027; US$ Mn)

Hospital Pharmacy

Retail Pharmacy

Others

Geography Segment (2017–2027; US$ Mn)

North America

U.S.
Canada

Europe

United Kingdom
Germany
Russia
France
Italy
Spain
Ukraine
Rest of Europe

Asia Pacific

China
Japan
Rest of Asia Pacific

Latin America (LATAM)

Brazil
Mexico
Rest of Latin America

Middle East and Africa (MEA)

GCC
Rest of MEA 

Justification for study?

  • The intention of the study is to give a comprehensive outlook of the global cilastatin sodium market
  • The overall segmentation of the cilastatin sodium market, by clinical application, distribution channel, and geography is minutely studied. Lower respiratory tract infections and hospital pharmacy are dominating the clinical application and distribution channel segments respectively
  • Growing incidence of lower respiratory tract infections worldwide
  • Significant increase in the number of individuals suffering from urinary tract infections further accentuate the market growth

Report gist?

  • The study of the global cilastatin sodium market includes qualitative analysis of factors such as drivers, restraints, and opportunities
  • The report covers the qualitative and quantitative analysis of the overall market segmented on the basis of clinical application and distribution channel and categorization of the same at the geography level
  • This research report presents the analysis of each segment from 2017 to 2027 in which 2019 is considered as the base year. The compounded annual growth rate is calculated for the respective segments from 2020 to 2027

The study includes the profiles of major market players with a significant global and regional presence along with top company positioning. 

Significant customers?

  • This study is suitable for industry participants and stakeholders in the pharmaceutical manufacturers actively engaged in the production and marketing of cilastatin sodium due to the  rising prevalence of lower respiratory tract infections worldwide
  • The report will benefit nephrologist prescribing cilastatin sodium in combination with imipenem for the treatment of urinary tract infections across the globe
  • Managers with financial institutions looking to publish recent and forecasted statistics pertaining to cilastatin sodium market
  • Financial institutions, venture capitalist, analysts, investors, government organizations, policymakers, regulatory authorities, researchers, looking for insights into the market to determine future strategies 

Segment Analysis

Lower respiratory tract infections are spearheading the clinical application segment for the cilastatin sodium market. According to the latest statistics provided by the World Health Organization (WHO) approximately, 1.4 million people die due to tuberculosis worldwide annually. Pneumonia is considered as the leading cause of death for children under the age of 5 years across the globe. Urinary tract infection will be showcasing sturdy market growth during the forecast period on account of the rising water pollution in the urban areas due to a significant increase in urbanization. The availability of poor civic amenities in the slum areas and unhygienic conditions are the major risk factors associated with the occurrence of urinary tract infections.

Hospital pharmacy is representing the largest market share in the distribution channel segment for the cilastatin sodium market. Drug overdose is associated with renal toxicity, hence it is advisable for precise drug dispensing of cilastatin sodium under the medical supervision of hospital pharmacists to prevent the occurrence of drug toxicity. Retail pharmacy is expected to register rampant market growth in the near future owing to the capability to provide low-cost generic medicines that are subjected to government subsidy and the ability to cater medicinal requirements for people residing in the remote locations.

North America is presently leading the geography segment for cilastatin sodium market growth. The rising prevalence of lower respiratory tract infections primarily drives the market growth in the region. As per the latest research citings presented by the National Institute of Health (NIH), the prevalence rate of lower respiratory tract infections in the children in the United States is 5772 per 100,000 children per year. Additionally, the affordable reimbursement scenario associated with the medicinal use of cisplatin sodium further accentuates the market growth in the region. Europe is considered as the second-largest regional segment for cilastatin sodium market on account of the rising prevalence of urinary tract infection across all age group residing in the region. Furthermore, the domicile of key players such as Fresenius Kabi., Pfizer, Inc., Merck KGaA., Sandoz, Inc., further propels the market growth in the region. The Asia Pacific is anticipated to be the fastest-growing regional segment for the cilastatin sodium market owing to the rising prevalence of bacterial septicemia and the flourishing generic drugs market.

Select License Type

$4,600
$6,600
$13,200

Safe and Secure SSL Encrypted

Have a Question?

We will help you find what you are looking for.

Call 1-518-730-1560

Contact sales

How can we help you?

Get in touch with us or find an office closest to you.